EBV TCR-T cells

EBV TCR-T cells are genetically engineered autologous or allogeneic T lymphocytes that express a transgenic or modified endogenous T-cell receptor (TCR) specific for antigens derived from the Epstein-Barr virus (EBV). These therapies are designed to recognize and kill EBV-infected or EBV-associated malignant cells by targeting viral antigens such as LMP1, LMP2, and other latent/lytic proteins presented on the surface of tumor or infected host cells. The approach is used primarily in the treatment of cancers associated with chronic active EBV infection—including nasopharyngeal carcinoma, certain gastric cancers, B-cell lymphomas (such as post-transplant lymphoproliferative disorder), and some autoimmune diseases. Mechanistically, these engineered T-cells bind to their cognate peptide-MHC complexes via their introduced high-affinity anti-EBV-specific receptors and mediate cytotoxicity against target cells. Some advanced versions may be "armored" with additional features such as secreted immune checkpoint inhibitors to enhance efficacy in immunosuppressive tumor microenvironments[3][7][9].

Other names

Epstein-Barr virus-specific TCR-T cellsEBV-specific T cell receptor engineered T cell therapyEBV-targeting TCR-T cells